Q-omics provides the consensus-scored RPL24P8 profile across patient tissues and cancer cell-line models. RPL24P8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL24P8 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPL24P8 RNA expression shows 15,948 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where RPL24P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL24P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL24P8 survival associations across molecular data types. RPL24P8 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL24P8 RNA expression–survival associations across cancer types. High RPL24P8 expression shows unfavorable associations in LUAD and LIHC, but favorable associations in SKCM, CESC, LUSC and UVM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL24P8 RNA expression.
This table summarizes RPL24P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL24P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL24P8 shows lower tumor expression in BRCA, LUSC and BLCA and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher RPL24P8 RNA expression in tumor versus normal tissue (log2 FC = +0.468, t-test p < 0.001).
This table shows molecular features associated with RPL24P8 in patient tissues and cancer cell lines. In patient samples, RPL24P8 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
